Table 4.

Proportions of participants reporting specific adverse events by intervention group.

Characteristics	Regimen started
	BAM/ETE	CAS/IMD	p-value*	Total
	N= 237	N= 196		N= 433
Adverse events, n(%)			0.064
Mild	8 (3.4%)	15 (7.7%)		23 (5.3%)
Moderate	0 (0.0%)	7 (3.6%)		7 (1.6%)
Severe	1 (0.4%)	0 (0.0%)		1 (0.2%)
Drug related	6 (2.5%)	19 (9.7%)	0.001	25 (5.8%)
Individual events, n(%)
Arthomyalgia	1 (0.4%)	2 (1.0%)	0.455	3 (0.7%)
Asthenia	0 (0.0%)	0 (0.0%)		0 (0.0%)
Chills	0 (0.0%)	3 (1.5%)	0.056	3 (0.7%)
Diarrhea	1 (0.4%)	1 (0.5%)	0.893	2 (0.5%)
Fever	4 (1.7%)	17 (8.7%)	<.001	21 (4.8%)
Nausea	0 (0.0%)	4 (2.0%)	0.027	4 (0.9%)
Sight decrease	0 (0.0%)	1 (0.5%)	0.271	1 (0.2%)
Headache	0 (0.0%)	1 (0.5%)	0.271	1 (0.2%)
Dyspnea	1 (11.1%)	1 (4.5%)	0.506	2 (6.5%)
Abdominal pain	1 (11.1%)	0 (0.0%)	0.118	1 (3.2%)
Hematoma	0 (0.0%)	0 (0.0%)		0 (0.0%)
Paraesthesia	1 (0.4%)	0 (0.0%)	0.363	1 (0.2%)
Itch	0 (0.0%)	0 (0.0%)		0 (0.0%)
Skin rash	0 (0.0%)	2 (1.0%)	0.119	2 (0.5%)
Dizziness	0 (0.0%)	0 (0.0%)		0 (0.0%)
Vomit	0 (0.0%)	1 (0.5%)	0.271	1 (0.2%)

^*Chi-square or Mann-Whitney test as appropriate.

BAM/ETE, bamlanivimab/etesevimab; CAS/IMD, casirivimab/imdevimab; IQR, interquartile range; BMI, body mass index; SpO2, peripheral oxygen saturation.